Disappointed no interim additional data given for

Quote:

---

Disappointed no interim additional data given for B-OM.

---

I wouldn't sweat the OM trial. It will end up with final numbers very close to the numbers given here:


Primary Efficacy Results Incidence of Severe OM (WHO Grade ≥ 3)

• Active Arm (Brilacidin): 2 of 9 patients (22.2 percent)
• Control Arm (Placebo): 7 of 10 patients (70 percent)

Secondary Efficacy Results Duration of Severe OM (WHO Grade ≥ 3)

• Active Arm (Brilacidin): Mean 10.5 days (Range 3 to 18 days; 2 patients)
• Control Arm (Placebo): Mean 14 days (Range 3 to 39 days; 7 patients)

That's plenty good for the current formulation. It will improve even further on these impressive results when they improve the formulation for it just like the UP formulation will improve on those impressive results.

All imho